Many studies report Liver kinase B1 (LKB1) plays a critical role in gastric cancer (GC). However, the relationship between LKB1 and the clinicopathological parameters of GC patients remains controversial. This meta-analysis aimed to investigate the above question and re-evaluate the prognostic significance of LKB1 in GC patients. We searched PubMed, Web of Science, Cochrane Library, Google Scholar, CNKI, and Wan Fang to identify relevant studies published before April 20, 2023. After careful screening, 11 studies involving 1767 patients were included. We found that LKB1 expression was significantly related to tumor size (OR 0.515; 95% CI 0.316–0.839;P< 0.01), differentiation (OR 0.643; 95% CI 0.521–0.794;P< 0.001), depth of invasion (OR 0.397; 95% CI 0.319–0.494;P< 0.001), lymph node metastasis (OR 0.487; 95% CI 0.397–0.598;P= 0.01), and TNM stage (OR 0.362; 95% CI 0.293–0.447;P= 0.006). However, LKB1 was unrelated to gender and age (P> 0.05). Moreover, low LKB1 expression was significant correlate with overall survival (OS) (HR = 1.59; 95% CI 1.29–1.96;P< 0.001). In conclusion, LKB1 expression is related to tumor size, differentiation, depth of invasion, lymph node metastasis, and TNM stage, and low LKB1 expression can predict a poor prognosis. LKB1 is a potentially valuable prognosis signature and therapeutic target in GC patients.